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Metabolic Syndrome and 
Pathogenesis of Obesity-Related 
Adverse Outcomes in Pregnancy
Motoi Sugimura
Abstract
Obese women with metabolic syndrome are at increased risk for cardio-
thrombo-metabolic dysfunction that leads to pregnancy-related venous throm-
boembolism (VTE), hypertensive disorders of pregnancy (HDP), and gestational 
diabetes mellitus (GDM). Indeed, maternal death secondary to a pregnancy-related 
VTE has an enormous impact on the childbearing population. Recent research has 
provided evidence that elucidates the pathogenesis of adverse outcomes in obese 
pregnant women with metabolic syndrome. The chronic inflammation elicited by 
dysregulated infiltration of macrophages into adipose tissue and increased thrombin 
generation by inflammatory cytokines with activation of the tissue factor pathway 
may play important roles in the pathogenesis; however, a simple question has yet 
to be answered. Specifically, “why does prepregnancy obesity increase the risk of 
pregnancy-related VTE in association with a high estrogenic and prothrombogenic 
state?” The present review of the extant literature has focused on further under-
standing obesity-related adverse outcomes in pregnancy by elucidating the underly-
ing pathogenesis of metabolic syndrome.
Keywords: obesity, metabolic syndrome, pregnancy-related venous 
thromboembolism, hypertensive disorders of pregnancy, gestational diabetes 
mellitus, inflammatory cytokines, thrombin formation, estrogen
1. Introduction
Epidemiologic studies in North America and Europe have shown that obesity 
increases the risk of venous thromboembolism (VTE) during pregnancy and the 
puerperium [1, 2], as well as postpartum hemorrhage [3]. Furthermore, women 
with prepregnancy obesity are also at increased risk of hypertensive disorders 
of pregnancy (HDP) [4, 5], including preeclampsia [6]. HDP is associated with 
placental abruption, which may lead to severe obstetric complications with dissemi-
nated intravascular coagulation (DIC) [7].
Recent research has shown that HDP and gestational diabetes mellitus (GDM) 
increase the risk of hypertension and diabetes mellitus (DM) later in life [8]. 
Conversely, maternal malnutrition during pregnancy because of inadequate dietary 
intake increases the risk of fetal growth restriction and low-birth-weight infants; 
it is increasingly evident that offspring are at increased risk of developing hyper-
tension and DM as well [9]. Indeed, addressing nutrition and weight gain before 
pregnancy are an important part of perinatal care [10].
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Thus, prepregnancy body weight and changes in weight gain during pregnancy 
may be indicators of maternal nutritional status, reflecting the balance between 
caloric intake and basal metabolism and exercise caloric expenditure [11].
Although hypertension and DM in obese patients with metabolic syndrome [12] 
are worrisome with respect to future health issues and increased mortality rate, 
pregnancy-related VTE has a greater and more direct impact on families among 
the childbearing population. Based on the annual report of the trends in maternal 
deaths and maternal mortality rates by cause of death from the Japan Ministry of 
Health, Labor, and Welfare in 2017 [13], the number of maternal deaths in Japan has 
decreased over time; however, 70% of maternal deaths are caused by hemorrhage, 
pulmonary embolism (including pulmonary thromboembolism and amniotic fluid 
embolism), and HDP. The percentage of maternal mortalities by cause of death has 
remained essentially unchanged over the past two decades, as shown in Figure 1. 
Increasing maternal age [14] due to changes in social lifestyle, advances in assisted 
reproductive medicine, and increased cesarean section rates may also be important 
factors in maternal deaths in Japan and developed countries worldwide [15]. Changes 
Figure 2. 
Pathogenesis of obesity-related adverse outcomes in pregnancy with a similar background to metabolic 
syndrome. Key words are pro-inflammatory state with insulin resistance and a prothrombotic state with a high 
estrogenic state in obese pregnant women.
Figure 1. 
Trends in maternal deaths and maternal mortality rates (per 100,000 total births) by causes of death in Japan.
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in dietary habits and a sedentary modern lifestyle are partly responsible for prepreg-
nancy obesity, which is followed by obesity-related adverse outcomes in pregnancy.
A growing number of epidemiologic observations on obesity in pregnancy have 
linked basic research findings [16] with the pathogenesis of obesity-related adverse 
outcomes in pregnancy with a similar background to metabolic syndrome [12, 17], 
as shown in Figure 2.
2. Obesity-related adverse outcomes in pregnancy
2.1  Pathogenesis of obesity-related adverse outcomes in pregnancy with a 
background of metabolic syndrome
In recent years, visceral fat has been regarded as one of the endocrine organs 
[18]. Visceral fat plays an important role in the pathogenesis of local and systemic 
chronic inflammation in obese patients [19]. A large number of studies have 
demonstrated a relationship between obesity and the pathophysiology underlying 
metabolic syndrome, specifically involving dysfunction of adipocytes with reduced 
adiponectin and innate immune cells with subsequent production of inflammatory 
cytokines [16]. Inflammatory cytokines induce tissue factor (TF) and enhanced 
thrombin generation by up-regulation of TF expression on various types of cells 
(Figure 3). Enhanced thrombin generation consecutively leads to inflammation, 
thrombus formation, and vascular damage due to activation of the cell signaling 
system via protein-activated receptors (PARs) [20] with TF as a receptor [21]. 
The induction of cytokines and thrombin generation interacts with the crosstalk 
between coagulation and inflammation [22, 23].
Adipose tissue formed by adipocytes with fat accumulation increases the 
level of triglycerides and decreases the adiponectin level. The tissue also activates 
immunocompetent cells, such as macrophages and mast cells, which produce and 
release pro-inflammatory cytokines (TNF-α, IL-6, IFN-ϒ, and IL-1β) [24]. The 
induction of TF on the cell surface of adipocytes and macrophages accelerates the 
prothrombotic state accompanied by thrombin generation. With respect to the high 
estrogenic state in pregnancy, prothrombotic conditions are likely to be induced in 
obese women because of the additional effects of dietary, social, environmental, 
and genetic factors which increase the risk of pregnancy-related VTE, although the 
precise mechanisms are still uncertain.
The most recent hypothesis regarding the pathogenesis of HDP suggests that 
impaired trophoblastic invasion into the inner myometrial portion of the spiral 
arteries causes the vessels to retain musculoelastic properties, thereby inducing 
hypoperfusion and hypoxia [25]. The subsequent release of inflammatory cytokines 
[26] promotes the excess production of soluble fms-like tyrosine kinase 1 (sFLT1) 
[27], which binds to VEGF as a decoy instead of VEGFR. The cytokines may also 
enhance maternal inflammatory responses and systemic endothelial dysfunction, 
leading to maternal symptom [28]. The resulting inflammatory cytokines induce 
TF, which subsequently initiates the TF-dependent coagulation pathway as the 
receptor for coagulation factors VIIa/VII [29]. In a vicious cycle, activation of the 
coagulation system and thrombin formation in the placental intervillous space 
enhances the production of sFLT1s through G protein-coupled protease-activated 
receptors [30] and causes further ischemic damage to trophoblastic cells in a hyper-
coagulable state [31, 32], as shown in Figure 4.
As one of the current hypotheses of the pathogenesis in pregnancy-related VTE 
and HDP, these observations provide the probable relationship between the high 
estrogenic state of pregnancy and prothrombotic conditions caused by chronic 
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inflammation due to the obesity with metabolic syndrome, although there is a lack 
of high-quality evidence (Figure 5).
2.2 Epidemiologic aspects of obesity-related adverse outcomes in pregnancy
Prepregnancy body mass index (BMI), weight changes during pregnancy, and 
perinatal prognosis are the epidemiologic aspects of obesity-related adverse out-
comes in pregnancy.
Although various academic societies have recommended guidelines for optimal 
weight gain and nutrition during pregnancy, the basic concept for the management 
of maternal nutrition has changed over time based on epidemiologic data. From the 
view of adverse maternal outcomes in North America in the first half of the twen-
tieth century, a weight gain of 9.1 kg throughout pregnancy was recommended to 
prevent HDP and operative deliveries, such as cesarean section and forceps deliver-
ies, because of macrosomic fetuses.
By the 1970s, at least 11.4 kg of weight gain during pregnancy was recommended 
to prevent spontaneous preterm births, fetal growth restriction, and adverse neona-
tal outcomes [33]. In the 1990s, the BMI classification was introduced as a means to 
establish optimal weight gain based on body weight and surface area. A weight gain 
of 11.5–16 kg was recommended in pregnant women with a normal prepregnancy 
BMI (19.8–26 kg/m2) [17].
During pregnancy, it is preferable to increase caloric intake by approximately 
390 kcal per day with small variations in addition to the daily caloric intake dur-
ing non-pregnancy [34]. Insufficient calorie intake leads to increased proteolysis 
and the lack of nutrition for fetal growth. Strict limitation of weight gain during 
pregnancy may increase the risk of preterm birth and fetal growth restriction [33], 
which is why an 11–16 kg weight gain is recommended for women with a normal 
prepregnancy BMI in North America [35]. Maternal weight gain with excessive 
calorie intake increases the risk of dystocia with macrosomic fetuses. Recent 
research has also suggested that maternal obesity increases the risk of childhood 
obesity [36] and the risk of autism spectrum [37].
Figure 3. 
Enhanced thrombin generation by tissue factor (TF) with activation of protease-activated receptor (PAR). 
The increased coagulation factors and reduced sensitivity to activated protein C in pregnancy accelerate the 
enhanced thrombin generation on tissue factor (TF) induced by (pro)-inflammatory cytokines (TNF-α, IL-6, 
IFN-ϒ, and IL-1β). The formed thrombin induces (pro)-inflammatory cytokines via activation of the protease-
activated receptor (PAR).
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The Institute of Medicine (IOM) guidelines in 2009 recommended that weight 
gain during pregnancy should be 0.3 kg/week for women who are overweight 
before pregnancy (25–29.9 kg/m2) and 0.18 kg/week for women who are obese 
Figure 4. 
Pathogenesis of hypertensive disorders of pregnancy (HDP). The important role of thrombin generation in 
the “two-stage disorder” theory for the pathogenesis of HDP. sEng: soluble endoglin, HIF-1α: hypoxia-induced 
factor, ET: endothelin, AT: angiotensin, sFLT1: soluble FLT1, PlGF: placental growth factor, VEGF: vascular 
endothelial growth factor, AT: antithrombin, TAT: thrombin-antithrombin complex, SFMC: soluble fibrin-
monomer complex, PIC: plasmin-α 2-plasmin inhibitor complex.
Figure 5. 
Pathogenesis of obesity-related adverse outcomes in pregnancy. The critical role of the induction of pro-
inflammatory cytokines by dysfunction of adipocytes with fat accumulation initiates the thrombin generation 
of tissue factor (TF) in various cells. The prothrombotic state with estrogen-induced hypercoagulability plays a 
role in the pathogenesis of venous thrombosis and hypertensive disorders of pregnancy.
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(>30 kg/m2) after the second trimester [38]. In addition, the IOM recommended 
an 11.3–15.8 kg weight gain during pregnancy for women with a normal prepreg-
nancy BMI (18.5–24.9 kg/m2), 6.8–11.3 kg for women who are overweight before 
pregnancy, and 4.9–9.0 kg for women who are obese before pregnancy. In 2015, the 
American College of Obstetricians and Gynecologists (ACOG) recommended a 
similar proposal in an ACOG Practice Bulletin [10]; however, it has been shown that 
women who are overweight and obese before pregnancy with inappropriate weight 
gain and loss during pregnancy are at increased risk for fetal growth restriction [39] 
due to pathologic placental changes [40].
In recent years, although underweight pregnant women with a prepregnancy 
BMI ≤18.5 kg/m2 have a reduced risk of HDP compared with obese pregnant 
women, a decrease in newborn birth weight in underweight pregnant women is 
associated with future health problems [41]. With respect to fetal programming, 
future health issues in adulthood should focus on the relationship between an 
increased risk for essential hypertension and DM [42] and low birthweight infants. 
Barker’s hypothesis in the 1980s [43] was based on epidemiologic observations of 
malnutrition during pregnancy in World War II and underweight children with an 
increased risk for hypertension (ischemic heart disease) and DM in adulthood.
Malnutrition is a significant problem in the developing countries. There is a 
relatively high prevalence of women of childbearing age who are obese worldwide 
[44]. During pregnancy, obesity with metabolic syndrome shares an underlying 
pathogenesis of cardio-thrombo-metabolic dysfunction and further worsens the 
health status. Specifically, pregnancy-related VTE and sudden maternal death have 
a greater impact [45] on the family and society compared with HDP and GDM.
2.3 Pregnancy-related VTE in the UK and North America
In Europe, especially in the United Kingdom, with a background of heritable 
thrombotic predisposition, medical journals have reported clinical cases of mater-
nal deaths due to VTE since the 1860s [46, 47]. National policy in the UK has pro-
vided guidance to reduce maternal mortality from pregnancy-related VTE [45, 48]. 
Epidemiologic and clinical studies have focused on pregnancy-related VTE [49] and 
showed the relationship between VTE and prepregnant obesity in pregnant women 
[50]. Multivariate analysis of prepregnant obese patients compared with non-obese 
patients as controls demonstrated that the adjusted odds ratio (aOR) is 1.93 (95% 
CI, 1.10–3.39) for VTE in the moderately obese group and 4.32 (95% CI, 1.26–14.84) 
for VTE in the highly obese group, as shown in 2008 [49].
Studies focusing on prepregnancy BMI and immobilization in the hospital 
showed a further increased risk of VTE during pregnancy and postpartum [49]. 
The aOR for VTE in pregnant women with a prepregnancy BMI >25 kg/m2 is 1.8 
(95% CI, 1.3–2.4). During immobilization with bed rest, the aOR for VTE increases 
to 62.3 (95% CI, 11.5–337.6) in patients with a BMI >25 kg/m2 [49]. The aOR for 
VTE in patients with a prepregnancy BMI >25 kg/m2 is 2.4 (95% CI, 1.7–3.3) during 
the postpartum period. The aOR is 40.1 (95% CI, 8.0–201.5) in a similar condition 
[49]. These epidemiologic data have supported the guidelines for the prevention 
and reduction in the risk of pregnancy-related VTE in the UK [51, 52] and North 
America [53].
The Royal College of Obstetricians and Gynecologists published data in 2015 
that indicated 60% of women who died of pulmonary thromboembolism (PE) 
between 2003 and 2008 were obese with a BMI ≥30 kg/m2. The prevalence of 
obesity with a similar BMI at 16–44 years of age in the population was 20% in 
the UK [52]. Pregnancy is a risk factor for VTE, and the risk increases in propor-
tion to the degree of obesity. Obese pregnant women had a higher aOR for PE 
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(aOR, 14.9; 95% CI, 3.0–74.8) than for deep vein thrombosis (DVT) (aOR, 4.4; 
95% CI, 1.6–11.9). The risk for pregnancy-related VTE is minimal in overweight 
pregnant women who had a prepregnancy BMI of 25–29.9 kg/m2; however, the 
guidance in the UK states that VTE risk in overweight women is extremely com-
mon, affecting nearly 50% in the childbearing population [52].
Obesity with a BMI of 3040 kg/m2 alone is classified as a lower risk category for 
VTE according to the guidelines [52]. However, pregnant women with a BMI of 
30–40 kg/m2 are classified as having an intermediate risk if they have two or more 
additional risk factors, including elective cesarean section, prolonged labor (>24 h), 
and operative delivery. These risk factors are more likely encountered in daily clini-
cal situations compared with a history of VTE.
The American College of Chest Physicians has also proposed similar guidelines 
to prevent pregnancy-associated VTE in obese pregnant women based on epidemio-
logic risk [51, 53]. Specifically, the American College of Chest Physicians showed 
that the occurrence of VTE is 3% among all women in the puerperium and the OR 
increases to >6 compared with women with a normal prepregnancy BMI if obese 
pregnant women with a prepregnancy BMI ≥30 kg/m2 are combined with those 
with other risk factors in women undergoing emergency cesarean section [53].
Epidemiologic observations have suggested that obesity and pregnancy are 
related to the prothrombotic state. The pathophysiology of metabolic syndrome 
may, in part, provide insight into understanding the increased hypercoagulable 
status with obese women in pregnancy with a high estrogenic state.
2.4 Obesity and estrogen
Estrogens are a type of sex steroid hormone. The endogenous estrogens are clas-
sified into estrone (E1), estradiol (E2), estriol (E3), and esterol (E4) [54]. Estrogens 
were initially thought to be female hormones; however, it has recently been shown 
that estrogens are involved not only in female physiologic functions but also in male 
reproductive physiologic functions. Recent studies have explored the bioactivity 
of estrogen in the neuroendocrine [55], vascular [56], musculoskeletal [57], and 
immune systems. Estrogen is associated with the pathogenesis of infertility, obesity 
[58], osteoporosis, endometriosis [59], and various types of cancers [60]. Estrogen 
crosses the cell membrane and binds to estrogen receptor (ER) α and ERβ in the cell 
as a ligand and estrogen receptors (mERs) on the cell membrane as ligands. Then, 
estrogen regulates the expression of gene products by binding to a specific DNA 
sequence, the hormone response element [61].
In pregnancy, the placenta and fetal adrenal cortex are the main estrogen pro-
duction sites. E3 is produced through the maternal liver, placenta, and fetal adrenal 
gland, although E2 is mainly produced by ovarian granulosa and capsular cells in 
women of reproductive age. By contrast, estrogen is produced in testicular stromal 
Sertoli cells in men [62]. The physiologic hormonal bioactivity is the highest in E2 
and then decreases in the order of E1 and E3.
Epidemiologic observations have shown that obesity increases the risk of 
estrogen-dependent breast [63] and endometrial cancer [64].
As described above, apoptotic cell death of adipocytes in adipose tissue by 
overstored fat in obese patients induces the migration of macrophages to the tissues 
[19, 65]. Consequently, chronic inflammation caused by pro-inflammatory cyto-
kines, such as TNFα and IL-8, leads to activation of the NF-κB signaling system and 
increased aromatase activity in various cells, including adipocytes, thus resulting 
in estrogen production [66]. Although the abnormal regulation of aromatase 
activity in adipose stromal cells in response to various inflammatory mediators 
involves a complex signaling pathway, visceral fat, which contributes to obesity, 
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plays an important role in the local and systematic production of estrogen [67]. The 
enhanced production of estrogen can be associated with the upregulated produc-
tion of coagulation factors that may lead to the induction of a prothrombotic state.
2.5 Estrogen and prothrombotic state
As described above, it is widely accepted that the risk of VTE is increased during 
pregnancy and the puerperium. The hypercoagulable state with elevated maternal 
estrogen levels during pregnancy is, in part, one of the explanations for the patho-
genesis, although the mechanism has not been fully elucidated.
Maternal estrogen levels during pregnancy increase enormously over the course 
of pregnancy, reaching concentrations approximately 100–500 times higher than 
non-pregnant levels [68]. Ninety percent of urinary estrogens are the conjugated 
form of E3, which has a 500- to 1000-fold higher concentration compared with 
non-pregnant women. The rapid increase in maternal estrogen levels is mainly due 
to the enhanced production of estrogen from the ovaries until the seventh week of 
gestation. Thereafter, the main origin of estrogen production shifts from the ovary 
to the fetal placental tissues [69].
LDL cholesterol is the main source of dehydroepiandrosterone sulfate 
(DHEA-S) in the fetal adrenal gland [69]. The 16α-hydroxylase converts a part of 
DHEA-S to 16OH-DHEA-S in the fetal liver, and the sulfatase and aromatase in the 
placenta convert the substrates to E2 and E3, which is followed by the secretion of 
E2 and E3 into the maternal blood [70]. Therefore, the fetal placental system gives 
rise to higher estrogen status, especially at the end of pregnancy.
By contrast, the high estrogen levels in pregnancy show abrupt reductions 
during the postpartum period because of the delivery of the placenta and fetus; 
the placenta is the main organ of estrogen production. Epidemiologic observa-
tions demonstrate that the risk of developing VTE during the puerperium is the 
highest within 1 week after delivery and then the risk of VTE decreases gradu-
ally 2 weeks after delivery. From the intrapartum to the postpartum period, the 
high levels of inflammatory cytokines associated with the onset of labor change 
dramatically [71]. Because of the changes in the levels of coagulation factors, 
endothelial injury, and stasis of blood flow [72], which are related to the onset 
of VTE, it is difficult to evaluate how estrogen-related coagulation factors are 
involved in the pathogenesis of VTE.
In 1961 [73], a patient with oral contraceptive (OC)-related VTE presented 
after taking an OC. Initially, the pathogenesis of VTE was understood to be simply 
due to dehydration caused by vomiting after taking the OC. Recently, upregulated 
production of coagulation factors by ethinyl E2 (EE2), a synthetic E2 that is less 
metabolized in the digestive system, is seen as a potential cause of VTE [74]. There 
is a significant correlation between the amount of EE2 contained in OCs and the 
increased risk of developing a VTE in an estrogen-dependent manner, which has led 
to the development of OCs containing ultra-low-dose estrogen (<50 μg) [75].
The current formulation of combined OCs (COCs) is a fourth-generation COC, 
which is defined as those containing a new type of progestin. However, different 
risks of VTE have been presented in COCs with different types of progestins instead 
of a low-dose estrogen (<50 μg) [76].
Some reports have suggested significant differences between second-genera-
tion COCs and third-generation COCs in the level of various coagulation factors 
[77]. These reports have speculated that the different progestins in COCs may 
be associated with the increased risk of OC-related VTE because of changes in 
coagulation. Prothrombin and factor VII levels are significantly increased in third-
generation COCs compared with that of second-generation COCs. Furthermore, 
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the activated protein C resistance by the aPTT method and the endogenous throm-
bin potential (ETP) method has been shown to be greater in third-generation 
COCs compared with that of second-generation COCs. These observations may 
indicate the probable relationship between female hormones and a thrombophilic 
tendency [77].
The second- and third-generation COCs have a different type of synthetic 
progestin. Although the mechanisms are not fully understood and are controversial 
[78], some studies have indicated that a small statistical difference exists in the risk 
of developing VTE [76].
Interestingly, unlike EE2, the endogenous estrogen 17β-E2 is rapidly metabolized 
by 17β dehydroxysteroid dehydrogenase [79] to E1 with less estrogenic activity. A 
COC containing a low dose of 17β-E2 has a relatively little effect on changes in the 
levels of coagulation factors [80]. Therefore, a COC containing 17β-E2 has been 
approved in Europe as a novel COC [81].
However, it is unclear how much of the endogenous estrogen (E2 and E3) in 
pregnant women magnifies the risk of pregnancy-related VTE compared with that 
of non-pregnant women. The changes in coagulation factors by female hormones 
do not provide strong evidence with the understanding of the mechanisms in the 
developing of VTE so far.
The changes in various markers of coagulation and fibrinolysis during the 
postpartum period of pregnancy have shown a significant increase in the levels of 
fibrinogen, FV, FVII, FVIII, and FX after pregnancy compared with that of non-
pregnancy [82].
Focusing on the inhibitory coagulation factor, protein S, which acts as a coen-
zyme in the activated protein C system, is significantly reduced during pregnancy 
[83]. In fact, 17β estradiol acts on ER-mediated suppression of the protein Sα gene 
(PROS1) mRNA and antigen production in a hepatocellular carcinoma-derived 
cultured cell line (HepG2) in an in vitro experimental system [84]. The experiment 
in a cultured cell line suggests that the increased estrogen during pregnancy can 
suppress protein S production. In addition, a report describes that a decrease in free 
protein S level due to an increase in C4b-binding protein during pregnancy is also 
associated with a decrease in protein S during pregnancy [85]. The changes in the 
various coagulation-fibrinolysis-related factors quickly return to the prepregnancy 
state during the postpartum period.
To confirm the hypothesis that the maternal high estrogenic conditions in 
pregnancy are related to the onset of the pregnancy-related VTE, previous research 
provided data on the changes in thrombin generation in an experiment with animals 
treated with exogenous estrogen [86] and the ex vivo determinants of thrombin 
potential reflecting prothrombotic conditions in pregnant women [87].
A variety of thrombin generation tests for evaluating the hypercoagulable state 
have been proposed for clinical samples derived from patients [88]. An ex vivo 
clotting assay has been the classical method, such as the aPTT and PT methods [88]. 
These clotting time assays initiate the coagulation reaction by adding a coagulation-
inducing substance, thromboplastin, into sample plasma and estimate the thrombin 
activity based on the fibrin clot formation time.
By contrast, as an alternative standardized method to evaluate the production 
of thrombin, the thrombin generation test by the endogenous thrombin potential 
(ETP)-based method was presented [89]. In this method, the extrinsic coagula-
tion cascade is activated in the presence of calcium ions by adding standardized 
phospholipids containing recombinant tissue factor into samples. The amount of 
thrombin generated is calculated from continuous measurement of the changes in 
fluorescence emission (or coloring) of the synthetic substrate. The activity mea-
sured over time and integrated is defined as ETP.
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In aPTT- and PT-based methods, by measuring the time to fibrin clot forma-
tion, these reactions terminate at the time of clot formation; however, thrombin 
continues to be formed after the termination of clot formation and the activity is 
maintained in the fibrin clot as the trapped form in α-2 macroglobulin. Compared 
with the thrombin activity measured by the PT-based method, the activity by the 
ETP-based method can reveal the approximate value of coagulation ability in ex 
vivo samples [89].
An animal experiment has shown that thrombin generation is upregulated in 
high estrogenic conditions [86]. The ETP-based assay detected changes in thrombin 
generation in non-pregnant rats treated with exogenous estrogen compared to 
controls to examine the direct effect of estrogen on the thrombin generation. A 
peak of ETP was observed on day 21 of administration compared to the control 
group. ETP in the administration group showed a significant increase as compared 
to that of the control group and returned to a similar level as the control group. By 
contrast, the conventional method did not show a difference in coagulation ability 
between the rats treated with estrogen and control. This animal experiment may 
simply indicate that estrogen induces a hypercoagulable state [86].
Other studies have demonstrated changes in thrombin generation, which is 
measured by an ETP-based method because the conventional method detects a 
small difference between thrombin generation in pregnant and non-pregnant 
women. Those studies showed that thrombin generation is significantly enhanced 
in late pregnancy and on day 1 postpartum compared to non-pregnancy. This obser-
vation indicates more directly that the hypercoagulable state can be induced during 
pregnancy and the puerperium [87].
The prothrombotic state is regulated by the balance between coagulation and 
inhibitory factors. This concept has focused on the resistance to the inhibitory regu-
lation of thrombin generation by activated protein C (APC) in studies of OC users 
[77, 90] because the reduced activity of APC can be associated with an increase in 
the risk of pregnancy-related VTE.
Like the COC studies, a clinical case report [91] and previous research have 
shown a significant decrease in sensitivity to APC [87] during the postpartum 
period. Decreased sensitivity to APC during pregnancy in clinical samples is par-
tially dependent on reduced protein S levels; however, it is difficult to conclude that 
resistance to APC in pregnancy and the puerperium is associated with the develop-
ment of pregnancy-related VTE. Although the phenomena of APC resistance may 
be relevant [87], the sample size measured in the study is too small to judge the 
impact of the mechanisms in VTE during pregnancy and the puerperium.
3. Conclusions
Epidemiologic observations have demonstrated that prepregnant obese women 
with underlying mechanisms of metabolic syndrome are at increased risk of 
pregnancy-related adverse outcomes of VTE, HDP, and GDM. Above all, maternal 
death by pregnancy-related VTE has an impact of great magnitude in the childbear-
ing population. The mechanisms underlying the pathogenesis of VTE remain poorly 
understood although the overlapping connections among obesity, high estrogen 
levels, and prothrombotic status are essential keys for expanding knowledge.
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